In the News

May 8. 2024 / Press Release

Athebio AG appoints Thomas Huber, PhD, as CEO

December 15. 2023 / Press Release

Athebio AG appoints Dr. Jens Hennecke to its Board of Directors

September 18. 2023 / Press Release

POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands

July 20. 2023 / Press Release

Shareholders of Athebio AG elect Dr. Hans-Peter Gerber as new member of the Board of Directors

March 28. 2023 / Press Release

Athebio Enters Development and License Agreement with Acuitas Therapeutics

March 20. 2023 / Press Release

Athebio AG appoints Dr. Hans-Peter Gerber as Scientific Advisor

September 15. 2022 / Press Release

Athebio Enters Collaboration Agreement with 3T Biosciences

February 4. 2022 / Press Release

Athebio Enters Research Agreement with REGENXBIO

January 6. 2022 / Press Release

Athebio AG appoints Dr. Victor Levitsky as Scientific Adviso